ISIN | LU2226245095 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | Galileo – Biotech Innovation Fund S USD |
Fund Provider |
IPConcept (Luxemburg) S.A.
Zürich, Switzerland Phone: +352 260248-1 E-Mail: info.lu@ipconcept.com Web: www.ipconcept.com |
Fund Provider | IPConcept (Luxemburg) S.A. |
Representative in Switzerland |
IPConcept (Schweiz) AG Zürich Phone: +41 044 224 32 09 |
Distributor(s) | Bellecapital AG |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark. |
Peculiarities |
Current Price * | 44.34 USD | 27.08.2025 |
---|---|---|
Previous Price * | 44.05 USD | 26.08.2025 |
52 Week High * | 57.51 USD | 20.09.2024 |
52 Week Low * | 32.42 USD | 09.04.2025 |
NAV * | 44.34 USD | 27.08.2025 |
Issue Price * | 44.34 USD | 27.08.2025 |
Redemption Price * | 44.34 USD | 27.08.2025 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 29,093,303 | |
Unit/Share Assets *** | 630,678 | |
Trading Information SIX |
YTD Performance | -3.44% |
30.12.2024 - 27.08.2025
30.12.2024 27.08.2025 |
---|---|---|
YTD Performance (in CHF) | -14.15% |
30.12.2024 - 27.08.2025
30.12.2024 27.08.2025 |
1 month | +1.51% |
28.07.2025 - 27.08.2025
28.07.2025 27.08.2025 |
3 months | +19.55% |
27.05.2025 - 27.08.2025
27.05.2025 27.08.2025 |
6 months | +4.26% |
27.02.2025 - 27.08.2025
27.02.2025 27.08.2025 |
1 year | -23.53% |
27.08.2024 - 27.08.2025
27.08.2024 27.08.2025 |
2 years | -17.78% |
28.08.2023 - 27.08.2025
28.08.2023 27.08.2025 |
3 years | -41.98% |
29.08.2022 - 27.08.2025
29.08.2022 27.08.2025 |
5 years | -70.44% |
31.03.2021 - 27.08.2025
31.03.2021 27.08.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Krystal Biotech Inc | 8.96% | |
---|---|---|
Arcellx Inc | 7.88% | |
Alnylam Pharmaceuticals Inc | 5.41% | |
BioNTech SE ADR | 4.87% | |
Vertex Pharmaceuticals Inc | 4.50% | |
Regeneron Pharmaceuticals Inc | 4.00% | |
Stoke Therapeutics Inc | 3.71% | |
Moderna Inc | 3.49% | |
Sarepta Therapeutics Inc | 3.16% | |
uniQure NV | 2.64% | |
Last data update | 31.01.2025 |
TER *** | 1.07% |
---|---|
TER date *** | 30.06.2025 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.60% |
Ongoing Charges *** | 1.04% |
SRRI ***
|
|
SRRI date *** | 31.07.2025 |